{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:39:35Z","timestamp":1790883575845,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01-CA129544"],"award-info":[{"award-number":["R01-CA129544"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01-CA172820"],"award-info":[{"award-number":["R01-CA172820"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.bbcan.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T15:45:55Z","timestamp":1470411955000},"page":"151-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Mechanism of antineoplastic activity of lonidamine"],"prefix":"10.1016","volume":"1866","author":[{"given":"Kavindra","family":"Nath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Nancolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Shestov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis B.","family":"Leeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Halestrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry D.","family":"Glickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0005","first-page":"418","article-title":"Anti-spermogenic activity of lonidamine (AF-1890) in rabbit","volume":"5","author":"Cioli","year":"1980","journal-title":"Ultramicroscopy"},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ijc.2910540126","article-title":"Potentiation of DNA-adduct formation and cytotoxicity of platinum-containing drugs by low pH","volume":"54","author":"Atema","year":"1993","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2016.08.001_bb0015","first-page":"2965","article-title":"Hydrogen ion-mediated enhancement of cytotoxicity of bis-chloroethylating drugs in rat mammary carcinoma cells in vitro","volume":"49","author":"Jahde","year":"1989","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2016.08.001_bb0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/BF00685157","article-title":"Nigericin enhances mafosfamide cytotoxicity at low extracellular pH","volume":"27","author":"Jahde","year":"1991","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0959-8049(93)90587-6","article-title":"Metabolic response of AH13r rat tumours to cyclophosphamide as monitored by pO2 and pH semi-microelectrodes","volume":"29A","author":"Jahde","year":"1992","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/nbm.3260","article-title":"Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan","volume":"28","author":"Nath","year":"2015","journal-title":"NMR Biomed."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/nbm.2824","article-title":"31P and 1H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan","volume":"26","author":"Nath","year":"2013","journal-title":"NMR Biomed."},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/nbm.3240","article-title":"Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin","volume":"28","author":"Nath","year":"2015","journal-title":"NMR Biomed."},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0045","doi-asserted-by":"crossref","first-page":"576","DOI":"10.2307\/3577306","article-title":"The role of low intracellular or extracellular pH in sensitization to hyperthermic radiosensitization","volume":"115","author":"Chu","year":"1988","journal-title":"Radiat. Res."},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0050","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2307\/3577758","article-title":"The role of intracellular pH and its variance in low pH sensitization of killing by hyperthermia","volume":"122","author":"Chu","year":"1990","journal-title":"Radiat. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2307\/3577906","article-title":"Modification of intracellular pH and thermosensitivity","volume":"129","author":"Lyons","year":"1992","journal-title":"Radiat. Res."},{"key":"10.1016\/j.bbcan.2016.08.001_bb0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000225883","article-title":"Radiosensitization of meth-a fibro-sarcoma in mice by lonidamine","volume":"41","author":"Kim","year":"1984","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0065","first-page":"1120","article-title":"Potentiation of radiation effects on 2 murine tumors by lonidamine","volume":"46","author":"Kim","year":"1986","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2016.08.001_bb0070","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/bjc.2013.391","article-title":"Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy","volume":"109","author":"Golding","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2016.08.001_bb0075","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02656739509022488","article-title":"Effect of whole-body hyperthermia on the pharmacokinetics and toxicity of lonidamine in dogs","volume":"11","author":"Price","year":"1995","journal-title":"Int. J. Hyperth."},{"issue":"2","key":"10.1016\/j.bbcan.2016.08.001_bb0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s002800050460","article-title":"Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs","volume":"38","author":"Price","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0085","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3892\/or.2015.4077","article-title":"Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids","volume":"34","author":"Cervantes-Madrid","year":"2015","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2016.08.001_bb0090","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s13277-014-2919-4","article-title":"Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes","volume":"36","author":"Sadeghi","year":"2015","journal-title":"Tumour Biol."},{"issue":"11 Pt 1","key":"10.1016\/j.bbcan.2016.08.001_bb0095","first-page":"4661","article-title":"Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells","volume":"41","author":"Floridi","year":"1981","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0100","first-page":"497","article-title":"Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells","volume":"66","author":"Floridi","year":"1981","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2016.08.001_bb0105","first-page":"1611","article-title":"Monocarboxylic acid transport","volume":"3","author":"Halestrap","year":"2013","journal-title":"Commun. Phys."},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2016.08.001_bb0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000238045","article-title":"Changes of energy metabolism in the germ cells and Ehrlich ascites tumor cells","volume":"27","author":"Floridi","year":"1981","journal-title":"Chemotherapy"},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.semcancer.2008.11.006","article-title":"Hexokinase-2 bound to mitochondria: cancer's stygian link to the \u201cWarburg effect\u201d and a pivotal target for effective therapy","volume":"19","author":"Mathupala","year":"2009","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2016.08.001_bb0120","series-title":"Membranes in Tumor Growth","first-page":"559","article-title":"Binding of lonidamine to Ehrlich ascites tumor and liver mitochondria","author":"Floridi","year":"1982"},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0003-9861(83)90272-2","article-title":"Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria","volume":"226","author":"Floridi","year":"1983","journal-title":"Arch. Biochem. Biophys."},{"issue":"13","key":"10.1016\/j.bbcan.2016.08.001_bb0130","first-page":"2814","article-title":"Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies","volume":"55","author":"Ben-Horin","year":"1995","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.bbcan.2016.08.001_bb0135","first-page":"5179","article-title":"Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy","volume":"60","author":"Mardor","year":"2000","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2016.08.001_bb0140","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1005819604858","article-title":"Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification","volume":"36","author":"Ben-Yoseph","year":"1998","journal-title":"J. Neuro-Oncol."},{"issue":"13","key":"10.1016\/j.bbcan.2016.08.001_bb0145","first-page":"3532","article-title":"Intracellular acidification of human melanoma xenografts by the respiratory inhibitor m-iodobenzylguanidine plus hyperglycemia: a 31P magnetic resonance spectroscopy study","volume":"60","author":"Zhou","year":"2000","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2016.08.001_bb0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1076-6332(03)80681-5","article-title":"Enhancement of hyperglycemia-induced acidification of human melanoma xenografts with inhibitors of respiration and ion transport","volume":"8","author":"Zhou","year":"2001","journal-title":"Acad. Radiol."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1042\/bj1480085","article-title":"Mitochondrial pyruvate carrier - kinetics and specificity for substrates and inhibitors","volume":"148","author":"Halestrap","year":"1975","journal-title":"Biochem. J."},{"issue":"10","key":"10.1016\/j.bbcan.2016.08.001_bb0160","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1074\/jbc.M115.701862","article-title":"Bonded cumomer analysis of human melanoma metabolism monitored by 13C NMR spectroscopy of perfused tumor cells","volume":"291","author":"Shestov","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bbcan.2016.08.001_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157125","article-title":"Comparison of the lonidamine potentiated effect of nitrogen mustard alkylating agents on the systemic treatment of DB-1 human melanoma xenografts in mice","volume":"11","author":"Nath","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bbcan.2016.08.001_bb0170","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/tx7004508","article-title":"Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards","volume":"21","author":"Loeber","year":"2008","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0175","first-page":"219","article-title":"The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake","volume":"15","author":"Skarsgard","year":"1995","journal-title":"Anticancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2016.08.001_bb0180","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1158\/1078-0432.CCR-04-2472","article-title":"Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells","volume":"11","author":"Wong","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2016.08.001_bb0185","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/bjc.1995.431","article-title":"The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours","volume":"72","author":"McCoy","year":"1995","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0190","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0006-2952(98)00306-2","article-title":"Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy","volume":"57","author":"Raghunand","year":"1999","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bbcan.2016.08.001_bb0195","first-page":"1194","article-title":"Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer","volume":"56","author":"Gerweck","year":"1996","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2016.08.001_bb0200","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0006-2952(98)00054-9","article-title":"Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism","volume":"56","author":"Floridi","year":"1998","journal-title":"Biochem. Pharmacol."},{"issue":"5\u20136","key":"10.1016\/j.bbcan.2016.08.001_bb0205","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.bjc.6690127","article-title":"Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG)","volume":"79","author":"Kuin","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0210","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1667\/0033-7587(2003)159[0328:TOAAAI]2.0.CO;2","article-title":"Tumor oxygenation and acidification are increased in melanoma xenografts after exposure to hyperglycemia and meta-iodo-benzylguanidine","volume":"159","author":"Burd","year":"2003","journal-title":"Radiat. Res."},{"issue":"7503","key":"10.1016\/j.bbcan.2016.08.001_bb0215","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.bbcan.2016.08.001_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071583","article-title":"Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review","volume":"8","author":"Franciosi","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bbcan.2016.08.001_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131207","article-title":"Phenformin induces cell cycle change, apoptosis, and mesenchymal-epithelial transition and regulates the AMPK\/mTOR\/p70s6k and MAPK\/ERK pathways in breast cancer cells","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"issue":"7506","key":"10.1016\/j.bbcan.2016.08.001_bb0230","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0235","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/0008-5472.CAN-14-2260","article-title":"Genetic disruption of lactate\/H+ symporters (MCTs) and their subunit CD147\/BASIGIN sensitizes glycolytic tumor cells to phenformin","volume":"75","author":"Marchiq","year":"2015","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2016.08.001_bb0240","doi-asserted-by":"crossref","first-page":"E534","DOI":"10.1002\/ijc.29193","article-title":"The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells","volume":"136","author":"Orecchioni","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2016.08.001_bb0245","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.bbcan.2016.08.001_bb0250","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1042\/BJ20151120","article-title":"The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters","volume":"473","author":"Nancolas","year":"2016","journal-title":"Biochem. J."},{"issue":"Pt 2","key":"10.1016\/j.bbcan.2016.08.001_bb0255","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3430281","article-title":"The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation","volume":"343","author":"Halestrap","year":"1999","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0260","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1074\/jbc.M115.697516","article-title":"Inhibition of mitochondrial complex II by the anti-cancer agent lonidamine","volume":"291","author":"Guo","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bbcan.2016.08.001_bb0265","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.bbabio.2013.01.004","article-title":"Differential effects of complex II on mitochondrial ROS production and their relation to cardioprotective pre- and postconditioning","volume":"1827","author":"Drose","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"5607","key":"10.1016\/j.bbcan.2016.08.001_bb0270","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.1079605","article-title":"Architecture of succinate dehydrogenase and reactive oxygen species generation","volume":"299","author":"Yankovskaya","year":"2003","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bbcan.2016.08.001_bb0275","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tibs.2014.06.005","article-title":"The pentose phosphate pathway and cancer","volume":"39","author":"Patra","year":"2014","journal-title":"Trends Biochem. Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2016.08.001_bb0280","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2174\/138920006779010601","article-title":"Endogenous glutathione adducts","volume":"7","author":"Blair","year":"2006","journal-title":"Curr. Drug Metab."},{"issue":"11","key":"10.1016\/j.bbcan.2016.08.001_bb0285","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1007\/s11064-012-0782-5","article-title":"Metabolic modeling of dynamic brain 13C NMR multiplet data: concepts and simulations with a two-compartment neuronal-glial model","volume":"37","author":"Shestov","year":"2012","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bbcan.2016.08.001_bb0290","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fonc.2016.00135","article-title":"13C MRS and LC-MS flux analysis of tumor intermediary metabolism","volume":"6","author":"Shestov","year":"2016","journal-title":"Front. Oncol."},{"issue":"15","key":"10.1016\/j.bbcan.2016.08.001_bb0295","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1002\/jnr.21269","article-title":"On the reliability of 13C metabolic modeling with two-compartment neuronal-glial models","volume":"85","author":"Shestov","year":"2007","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0300","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/nbm.2825","article-title":"Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma","volume":"26","author":"Lee","year":"2013","journal-title":"NMR Biomed."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0305","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0014-5793(75)80674-0","article-title":"The involvement of mitochondrial pyruvate transport in the pathways of gluconeogenesis from serine and alanine in isolated rat and mouse liver cells","volume":"53","author":"Mendes-Mourao","year":"1975","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0310","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1358\/dot.2003.39.3.799451","article-title":"Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors","volume":"39","author":"Di Cosimo","year":"2003","journal-title":"Drugs Today"},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0315","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/bjc.1991.356","article-title":"A phase-II clinical and pharmacokinetic study of lonidamine in patients with advanced breast-cancer","volume":"64","author":"Mansi","year":"1991","journal-title":"Br. J. Cancer"},{"issue":"Suppl. 7","key":"10.1016\/j.bbcan.2016.08.001_bb0320","first-page":"S12","article-title":"The development of lonidamine for benign prostatic hyperplasia and other indications","volume":"7","author":"Roehrborn","year":"2005","journal-title":"Rev. Urol."},{"issue":"2 Suppl. 4","key":"10.1016\/j.bbcan.2016.08.001_bb0325","first-page":"18","article-title":"Toxicity and clinical tolerance of lonidamine","volume":"18","author":"Robustelli della Cuna","year":"1991","journal-title":"Semin. Oncol."},{"issue":"2 Suppl. 4","key":"10.1016\/j.bbcan.2016.08.001_bb0330","first-page":"2","article-title":"Lonidamine: an overview","volume":"18","author":"Silvestrini","year":"1991","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0335","first-page":"55","article-title":"Modulation of glycolysis in neuroepithelial tumors","volume":"33","author":"Floridi","year":"1989","journal-title":"J. Neurosurg. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0340","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/bjc.1991.356","article-title":"A phase II clinical and pharmacokinetic study of lonidamine in patients with advanced breast cancer","volume":"64","author":"Mansi","year":"1991","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2016.08.001_bb0345","first-page":"436","article-title":"Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer","volume":"41","author":"Gatzemeier","year":"1991","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"10.1016\/j.bbcan.2016.08.001_bb0350","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s002800050747","article-title":"Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study","volume":"41","author":"Dogliotti","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.bbcan.2016.08.001_bb0355","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/00001813-199711000-00005","article-title":"Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM)","volume":"8","author":"Gebbia","year":"1997","journal-title":"Anti-Cancer Drugs"},{"issue":"10","key":"10.1016\/j.bbcan.2016.08.001_bb0360","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/0959-8049(95)00200-3","article-title":"Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer","volume":"31A","author":"Lopez","year":"1995","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0365","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/A:1006213815195","article-title":"Weekly epirubicin plus lonidamine in advanced breast carcinoma","volume":"56","author":"Nistico","year":"1999","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.bbcan.2016.08.001_bb0370","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1200\/JCO.1999.17.5.1526","article-title":"Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group","volume":"17","author":"Comella","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0375","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/030089169107700113","article-title":"Lonidamine in non-small-cell lung cancer: a phase II study","volume":"77","author":"Contu","year":"1991","journal-title":"Tumori"},{"issue":"4","key":"10.1016\/j.bbcan.2016.08.001_bb0380","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/030089169908500405","article-title":"Treatment of inoperable non-small cell lung carcinoma stage IIIb and IV with cisplatin, epidoxorubicin, vindesine and lonidamine: a phase II study","volume":"85","author":"Portalone","year":"1999","journal-title":"Tumori"},{"issue":"6B","key":"10.1016\/j.bbcan.2016.08.001_bb0385","first-page":"3865","article-title":"Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer","volume":"16","author":"Bottalico","year":"1996","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2016.08.001_bb0390","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1200\/JCO.1997.15.10.3208","article-title":"Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum","volume":"15","author":"De Lena","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0395","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0959-8049(00)00400-7","article-title":"Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study","volume":"37","author":"De Lena","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2016.08.001_bb0400","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/0959-8049(94)00231-S","article-title":"Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer","volume":"30A","author":"Gadducci","year":"1994","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2016.08.001_bb0405","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/0959-8049(94)90116-3","article-title":"Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX+LND) in recurrent and\/or metastatic carcinoma of the head and neck","volume":"30A","author":"Colella","year":"1994","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0410","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0360-3016(94)90225-9","article-title":"Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer","volume":"29","author":"Magno","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2016.08.001_bb0415","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000225898","article-title":"Lonidamine and radiotherapy in head and neck cancers. A pilot study","volume":"41","author":"Magno","year":"1984","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0420","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1006063412726","article-title":"Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial","volume":"49","author":"Amadori","year":"1998","journal-title":"Breast Cancer Res. Treat."},{"issue":"20","key":"10.1016\/j.bbcan.2016.08.001_bb0425","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2002.08.012","article-title":"Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design","volume":"20","author":"Berruti","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2 Suppl. 4","key":"10.1016\/j.bbcan.2016.08.001_bb0430","first-page":"66","article-title":"Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study","volume":"18","author":"Calabresi","year":"1991","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2016.08.001_bb0435","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1200\/JCO.1996.14.4.1165","article-title":"Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial","volume":"14","author":"Dogliotti","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2016.08.001_bb0440","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0959-8049(00)00068-X","article-title":"FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results","volume":"36","author":"Pacini","year":"2000","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2016.08.001_bb0445","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/0959-8049(94)00286-E","article-title":"A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG)","volume":"30A","author":"Buccheri","year":"1994","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0450","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/030089169908500306","article-title":"The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force","volume":"85","author":"De Marinis","year":"1999","journal-title":"Tumori"},{"issue":"2 Suppl. 4","key":"10.1016\/j.bbcan.2016.08.001_bb0455","first-page":"42","article-title":"Phase III trial with and without lonidamine in non-small cell lung cancer","volume":"18","author":"Gatzemeier","year":"1991","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2016.08.001_bb0460","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/(SICI)1097-0142(19960701)78:1<63::AID-CNCR11>3.0.CO;2-5","article-title":"Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial","volume":"78","author":"Ianniello","year":"1996","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2016.08.001_bb0465","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0360-3016(94)90394-8","article-title":"A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer","volume":"29","author":"Scarantino","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.bbcan.2016.08.001_bb0470","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1358\/dot.2003.39.3.799451","article-title":"Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors","volume":"39","author":"Di Cosimo","year":"2003","journal-title":"Drugs Today (Barc.)"},{"issue":"22","key":"10.1016\/j.bbcan.2016.08.001_bb0475","first-page":"6587","article-title":"Phase I trial of lonidamine with whole body hyperthermia in advanced cancer","volume":"48","author":"Robins","year":"1988","journal-title":"Cancer Res."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X16300592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X16300592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T03:25:45Z","timestamp":1568258745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X16300592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0304419X16300592"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2016.08.001","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism of antineoplastic activity of lonidamine","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}